Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABV-1502
- Development stage
- Unknown
- Lead developer
- ABVC BioPharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
ABV-1502 is a combination therapy developed by American BriVision (a subsidiary of American BriVision (Holding) Corporation) in collaboration with BioLite for the treatment of Major Depressive Disorder (MDD). The product candidate consists of a low-dose of the NMDA receptor antagonist ketamine combined with BLI-1005, a proprietary botanical extract derived from the fungus *Poria cocos*. The rationale behind the combination is to leverage the rapid-acting antidepressant properties of ketamine while utilizing the neuro-modulatory effects of BLI-1005 to potentially enhance efficacy, extend the duration of response, and mitigate the dissociative side effects typically associated with ketamine monotherapy. ABV-1502 is part of a broader pipeline of clinical-stage assets licensed by BriVision from BioLite, targeting central nervous system disorders and oncology.
- Other names
- BLI-1005 + ketamine
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on ABV-1502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABV-1502.